Innovative Compounding Pharmacy Testosterone Cypionate Recall: Lack of Sterility Assurance
Innovative Compounding Pharmacy recalls testosterone cypionate injections due to lack of sterility assurance. Affected lots expire by April 2020. Contact for details.
Lower-risk recall
Lack of Assurance of Sterility
Contact the company
What happened, in plain English
Innovative Compounding Pharmacy is recalling testosterone cypionate injections because they may not be sterile. This could lead to infections if used. People with prescriptions for this medication should check their lot numbers. Read more at govinfonow.com/recall/37208-innovative-compounding-pharmacy-testosterone-cypionate-recall-lack-of-sterility-assurance.
Source Summary by GovInfoNow · govinfonow.com/recall/37208-innovative-compounding-pharmacy-testosterone-cypionate-recall-lack-of-sterility-assurance · Updated October 5, 2026 · FDA enforcement record: FDA #D-1098-2020
Cite this page
“Innovative Compounding Pharmacy Testosterone Cypionate Recall: Lack of Sterility Assurance.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/37208-innovative-compounding-pharmacy-testosterone-cypionate-recall-lack-of-sterility-assurance. Based on FDA recall #D-1098-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1098-2020%22&limit=1).
Why it’s dangerous
The product may not be sterile, which could cause infections if injected. This is a risk for people receiving the medication through injection.
Who’s affected
People with prescriptions for testosterone cypionate injections from Innovative Compounding Pharmacy are affected. Those using the product without a prescription are not at risk.
How to tell if you have this one
Check the lot number on the label: 11152019@41, 12042019@12, 12172019@9, 01032020@49, or 01162020@55. These lots expire by April 2020.
- Brand
Innovative Compounding Pharmacy- Category
Drug
All 5 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Terminated- Distribution
Patient Distribution list includes addresses in the following states: CA, ME, TX
| Recall number | Product, codes & lots |
|---|---|
| D-1095-2020 | Methylcobalamin Soln. 1000 mcg/ml, 10 mL, Injectable, Rx only, INNOVATIVE COMPOUNDING PHARMACY, 41536 EASTMAN DRIVE SUITE A MURRIETA , CA 92562 951-304-9530; Lot #: 02262020@51, Expires after 05-26-2020; Lot # 01032020@53, Expires after 04-02-2020; Lot # 01162020@57, Expires after 04-15-2020 |
| D-1096-2020 | MIC-8 (Methionine 15mg /Inositol 50 mg/Choline 100 mg/B-12 6mcg/ml) , 10 mL, Injectable, Rx only, INNOVATIVE COMPOUNDING PHARMACY, 41536 EASTMAN DRIVE SUITE A MURRIETA , CA 92562 951-304-9530; Lot #: 03022020@64, Expires after 05-18-2020; Lot # 01032020@51, Expires after 04-02-2020 |
| D-1097-2020 | Hydroxyprogesterone Caproate (BUD) 350mg/ml , 4 mL, Injectable, Rx only, INNOVATIVE COMPOUNDING PHARMACY, 41536 EASTMAN DRIVE SUITE A MURRIETA , CA 92562 951-304-9530; Lot #: 02212020@2, Expires after 04-21-2020; Lot #: 02262020@52 Expires after 04-26-2020 |
| D-1098-2020 | Testosterone Cypionate In Sesame Oil 200mg/ml, 5 mL, Injectable, Rx only, INNOVATIVE COMPOUNDING PHARMACY, 41536 EASTMAN DRIVE SUITE A MURRIETA , CA 92562 951-304-9530; Lot #: 11152019@41,Expires after 04-07-2020; Lot # 12042019@12, Expires after 04-26-2020; Lot # 12172019@9, Expires after 05-09-2020; Lot # 01032020@49, Expires after 05-26-2020; Lot # 01162020@55, Expires after 06-08-2020 |
| D-1099-2020 | Alprostadil 10mcg/Papaverine 30mg/Phentolamine 1mg/ml lnj Soln, 5 mL, Injectable, Rx only, INNOVATIVE COMPOUNDING PHARMACY, 41536 EASTMAN DRIVE SUITE A MURRIETA , CA 92562 951-304-9530; Lot #02282020@30, Expires after 04/28/2020 |
What to do — step by step
Check Lot Number
Look for lot numbers 11152019@41, 12042019@12, 12172019@9, 01032020@49, or 01162020@55 on the label.
Where it went and when
Where it was distributed
Distributed in 3 states.
FDA distribution: “Patient Distribution list includes addresses in the following states: CA, ME, TX” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: California, Maine, Texas.
Recall timeline
FDA terminated this recall 3.8 years after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1098-2020 (March 26, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1098-2020 to see it in context.
- Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.